MedTrace Logo

Genetically Informed Smoking Cessation Trial

NCT02351167 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 822

Last updated 2020-09-22

Study results available
· View outcomes & findings →

Summary

The investigators' goal is to identify the most appropriate smoking cessation treatments for smokers based on genetic information. Smokers try to quit smoking but relapses are common.

Conditions

  • Smoking Cessation

Interventions

DRUG

Combination NRT (Nicotine patch, Nicotine lozenge)

DRUG

Varenicline

DRUG

Placebo

BEHAVIORAL

Intensive smoking counseling

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Li-Shiun Chen, M.D. · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-20
Primary Completion
2018-12-26
Completion
2019-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02351167 on ClinicalTrials.gov